12:00 AM
 | 
Jun 13, 2005
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 6/10 cls
Alteon (ALT) Rodman Ren Benjamin Discontinued NA -54% $0.31
Benjamin terminated coverage after ALT discontinued the Phase IIb SPECTRA trial of its alagebrium to treat uncontrolled systolic hypertension. The company also announced that FDA had placed the Phase IIa EMERALD trial...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >